Key facts
- Notable investors include Anji Liangshan Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Changbai Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Changbai Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Changbai Technology
Provider of biomedical evaluation services intended for infectious disease research. The company offers pharmacodynamic assessment, clinical biosample analysis, and microbial agent release testing across over 100 evaluation pipelines, enabling pharmaceutical and veterinary research organizations to streamline drug and vaccine development, validate efficacy, and accelerate regulatory compliance through integrated data processing, technical consulting, and AI-driven software tools.
- Sector
- Healthcare
- HQ
- Huzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Changbai Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Changbai Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Changbai Technology in its N-PORT filings yet. We sweep new filings monthly.